Abivax: two appointments to the Board of Directors
"As we move forward with our Phase 3 program for obefazimod in ulcerative colitis, their extensive expertise will be invaluable in driving the company's strategic priorities", comments CEO Marc de Garidel.
These appointments, replacing Joy Amundson and Jean-Jacques Bertrand, are accompanied by a complete overhaul of the composition of the Audit Committee and the Recruitment and Remuneration Committee.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction